Aim: To assess the efficacy of Semaglutide on liver steatosis/fibrosis indexes.

Methods: Observational, multicenter study. Steatosis/fibrosis were determined by HSI (<30 rule out, >36 steatosis) and FIB-4 (<1.3 rule out, >2.67 fibrosis) .

Results: 213 patients (46.9% women) , age 64 (19) years. Variables and 24 wk changes are shown in table 1. 100% of patients had altered steatosis biomarkers (HSI 47.9 (8.2)) , 10.8% fibrosis (FIB-4> 2.76) . A significant reduction in HSI [-2.36 (95%CI 1.83-2.9) p<0.0000] and FIB-4 [-0.075 (95%CI0.015-0.14) p<0.016] were found (Table 1) . There was a correlation between weight loss and HSI, GGT or TyG improvement (figure 1) .

Conclusion: Our results show a beneficial effect of Semaglutide on steatosis that goes beyond glucose control, and it is related mainly with weight loss and decline in biomarkers.


J.Carretero gomez: None. F.Carrasco-sánchez: None. J.Fernandez: Advisory Panel; Boehringer Ingelheim International GmbH, Daiichi Sankyo, Lilly Diabetes, Novartis Pharmaceuticals Corporation, Sanofi Genzyme, Speaker's Bureau; Amgen Inc., Novo Nordisk Foundation. P.Casado: None. P.Diabetes, nutrition and obesity working group of s: n/a. J.Arevalo lorido: None. J.Miramontes gonzález: None. J.Segí-ripoll: None. J.Ena: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at